Transferrin receptor 1-targeted polymersomes therapy for colorectal cancer
Source abstract
Abstract
Colorectal cancer (CRC) ranks among the most common cancers and is the second leading cause of cancer-related deaths. The high mortality associated with CRC is attributed mainly to difficulties in early detection and lack of effective targeted therapies. The Transferrin receptor 1 (TfR1) is particularly attractive as a therapy target given its notable overexpression in tumor cells, particularly in CRC. This study explored the potential of a polymeric nanoparticle (PSomes)-based drug delivery system targeting TfR1 to improve the precision and efficacy of CRC treatment. For this study, we used two human CRC cell lines (HT-29, and HCT116), a healthy human intestinal epithelial cell line (hIECs), and a murine CRC cell line (MC38). We engineered PSomes composed of poly (ethylene glycol) (PEG) and poly (lactic acid) (PLA), functionalized with the T7 peptide to enhance their specificity for TfR1-expressing cells. Targeting efficiency of these PSomes was assessed across all cell lines by evaluating the cellular uptake using flow cytometry. Upon establishing the optimal formulation for these NPs for TfR1-targeting, we encapsulated doxorubicin (DOX) to assess their therapeutic potential. Both in vitro and in vivo experiments demonstrated that DOX loaded TfR1-targeted PSomes delivered DOX to CRC cells, leading to efficient induction of CRC cell death, reducing tumor growth and improving survival rates, compared to the control groups. These results highlight the promise of TfR1-targeted PSomes as a precise strategy for CRC therapy, offering enhanced treatment efficacy while reducing systemic toxicity. This novel approach could lead to more targeted and less harmful cancer treatments.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Colorectal Cancer Treatments and Studies · Cancer Treatment and Pharmacology · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer10.1016/j.biopha.2023.114786 ↗
2. Heterogeneity in colorectal cancer: a challenge for personalized medicine?10.3390/ijms19123733 ↗
3. Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer10.1038/s41467-024-48706-2 ↗
4. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies10.3390/cancers14071732 ↗
5. Colorectal cancer10.1038/nrdp.2015.65 ↗
6. Colorectal cancer immunotherapy: options and strategies10.3389/fimmu.2020.01624 ↗
7. Chemotherapy side-effects: not all DNA damage is equal10.3390/cancers14030627 ↗
8. Recent advances in doxorubicin formulation to enhance pharmacokinetics and tumor targeting10.3390/ph16060802 ↗
9. Doxorubicin—an agent with multiple mechanisms of anticancer activity10.3390/cells12040659 ↗
10. Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity10.1038/s41598-017-03284-w ↗
11. Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer10.1186/s12951-022-01586-4 ↗
12. P-glycoprotein and cancer: what do we currently know?10.1016/j.heliyon.2022.e11171 ↗
13. The role of p53 signaling in colorectal cancer10.3390/cancers13092125 ↗
14. Epigenetic and genetic features of 24 colon cancer cell lines10.1038/oncsis.2013.35 ↗
15. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors10.1186/s12864-019-6344-3 ↗
16. Apoptosis deregulation and the development of cancer multi-drug resistance10.3390/cancers13174363 ↗
17. Transferrin receptor 1 in cancer: a new sight for cancer therapy
18. Smart nanoparticles for cancer therapy10.1038/s41392-023-01642-x ↗
19. Polymersomes as the next attractive generation of drug delivery systems: definition, synthesis and applications10.3390/ma17020319 ↗
20. Polymeric nanocarriers: a promising tool for early diagnosis and efficient treatment of colorectal cancer10.1016/j.jare.2021.11.008 ↗
21. Transferrin receptor targeting segment T7 containing peptide gene delivery vectors for efficient transfection of brain tumor cells10.1080/10717544.2022.2102696 ↗
22. T7 peptide-modified macrophage membrane-coated nanoplatform for enhanced glioma treatment10.1016/j.ejpb.2024.114527 ↗
23. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting10.1016/j.ijpharm.2013.07.019 ↗
24. Critical assessment of purification processes for the robust production of polymeric nanomedicine10.1016/j.ijpharm.2024.124975 ↗
25. Assessment of in vitro release testing methods for colloidal drug carriers: the lack of standardized protocols10.3390/pharmaceutics16010103 ↗
26. Nanoparticle size effects in biomedical applications10.1021/acsanm.1c00987 ↗
27. Polymersomes and their applications in cancer delivery and therapy10.2217/nnm.15.110 ↗
28. Transferrin receptors targeting peptide (T7 peptide) surface-modified sorafenib nanoliposomes enhance the anti-tumor effect in colorectal cancer10.1080/10837450.2020.1786116 ↗
29. Transferrin receptor‐mediated iron uptake promotes Colon tumorigenesis
30. Encapsulation, release, and cytotoxicity of doxorubicin loaded in liposomes, micelles, and metal-organic frameworks: a review10.3390/pharmaceutics14020254 ↗
31. Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment10.1016/j.jconrel.2024.07.004 ↗
32. A nanobody–bioorthogonal catalyst conjugate triggers spatially confined prodrug activation for combinational chemo-immunotherapy10.1021/acs.jmedchem.3c00557 ↗
33. Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo10.1016/j.jconrel.2020.01.012 ↗
34. da Silva · Polymersomes for Targeted Drug and Gene Delivery Systems · 2022 · 399
35. Tetrac-conjugated polymersomes for integrin-targeted delivery of camptothecin to colon adenocarcinoma in vitro and in vivo10.1016/j.ijpharm.2017.09.039 ↗
36. Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician10.3389/fphar.2021.670479 ↗
37. Regulated cell death pathways in doxorubicin-induced cardiotoxicity10.1038/s41419-021-03614-x ↗
38. The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: role of programmed cell death10.1016/j.cstres.2024.09.001 ↗
39. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer10.1016/j.biopha.2022.113690 ↗
40. Co-delivery of doxorubicin and VEGF siRNA using carcinoembryonic antigen-targeted chitosan nanoparticles for colorectal cancer
41. Stealth nanoparticles in oncology: facing the PEG dilemma10.1016/j.jconrel.2022.09.002 ↗
42. Strategies to improve tumor penetration of nanomedicines through nanoparticle design10.1002/wnan.1519 ↗
43. The role of micelle size in tumor accumulation, penetration, and treatment10.1021/acsnano.5b02017 ↗